Activirosomes Limited develops effective, inherently safe, affordable vaccines against viral infectious diseases.
Their licenced "Active Virosome" technology platform is a simple, safe and efficient biotechnology for producing candidate vaccines. It can be modified easily to produce vaccines for new viral infection outbreaks, or for personalised therapies, simply by slotting in a "cassette" of suitable genetic information.
Active Virosomes have many advantages compared to other vaccines against viral infections, including their safety and low cost of development and manufacture. This makes them particularly suitable for development and use in low and middle income countries which suffer from viral infections carried by mosquitos: it also makes them potentially disruptive in making modern cancer therapies affordable to all.
Norwich Research Park